Literature DB >> 28893776

Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance.

John Z Metcalfe1, Elizabeth Streicher2, Grant Theron2, Rebecca E Colman3, Renee Penaloza4, Christopher Allender5, Darrin Lemmer5, Robin M Warren2, David M Engelthaler5.   

Abstract

Multidrug-resistant tuberculosis (TB) presents a major public health dilemma. Heteroresistance, the coexistence of drug-resistant and drug-susceptible strains or of multiple drug-resistant strains with discrete haplotypes, may affect accurate diagnosis and the institution of effective treatment. Subculture, or passage of cells onto fresh growth medium, is utilized to preserve Mycobacterium tuberculosis cell lines and is universally employed in TB diagnostics. The impact of such passages, typically performed in the absence of drug, on drug-resistant subpopulations is hypothesized to vary according to the competitive costs of genotypic resistance-associated variants. We applied ultradeep next-generation sequencing to 61 phenotypically rifampin-monoresistant (n = 17) and preextensively (n = 41) and extensively (n = 3) drug-resistant isolates with presumptive heteroresistance at two time points in serial subculture. We found significant dynamic loss of minor-variant resistant subpopulations across all analyzed resistance-determining regions, including eight isolates (13%) whose antibiogram data would have transitioned from resistant to susceptible for at least one drug through subculture. Surprisingly, some resistance-associated variants appeared to be selected for in subculture.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  drug-resistant tuberculosis; gyrA; heteroresistance; rpoB; rrs

Mesh:

Substances:

Year:  2017        PMID: 28893776      PMCID: PMC5655066          DOI: 10.1128/AAC.00888-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Antibiotic resistance in the absence of selective pressure.

Authors:  S H Gillespie
Journal:  Int J Antimicrob Agents       Date:  2001-03       Impact factor: 5.283

2.  Tests for streptomycin sensitivity of tubercle bacilli in tween 80 albumin liquid medium.

Authors:  D A MITCHISON
Journal:  Lancet       Date:  1949-10-15       Impact factor: 79.321

3.  Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.

Authors:  John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

4.  The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan
Journal:  Science       Date:  2006-06-30       Impact factor: 47.728

5.  Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.

Authors:  P Mondon; R Petter; G Amalfitano; R Luzzati; E Concia; I Polacheck; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from Mycobacterium tuberculosis grown in vitro: implications for virulence studies.

Authors:  Pilar Domenech; Michael B Reed
Journal:  Microbiology (Reading)       Date:  2009-08-06       Impact factor: 2.777

7.  Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations.

Authors:  Leen Rigouts; Mourad Gumusboga; Willem Bram de Rijk; Elie Nduwamahoro; Cécile Uwizeye; Bouke de Jong; Armand Van Deun
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

8.  Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.

Authors:  Maha R Farhat; Karen R Jacobson; Molly F Franke; Devinder Kaur; Alex Sloutsky; Carole D Mitnick; Megan Murray
Journal:  J Clin Microbiol       Date:  2016-01-13       Impact factor: 5.948

9.  Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing.

Authors:  Rebecca E Colman; James M Schupp; Nathan D Hicks; David E Smith; Jordan L Buchhagen; Faramarz Valafar; Valeriu Crudu; Elena Romancenco; Ecaterina Noroc; Lynn Jackson; Donald G Catanzaro; Timothy C Rodwell; Antonino Catanzaro; Paul Keim; David M Engelthaler
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

10.  Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis.

Authors:  Maha R Farhat; B Jesse Shapiro; Karen J Kieser; Razvan Sultana; Karen R Jacobson; Thomas C Victor; Robin M Warren; Elizabeth M Streicher; Alistair Calver; Alex Sloutsky; Devinder Kaur; Jamie E Posey; Bonnie Plikaytis; Marco R Oggioni; Jennifer L Gardy; James C Johnston; Mabel Rodrigues; Patrick K C Tang; Midori Kato-Maeda; Mark L Borowsky; Bhavana Muddukrishna; Barry N Kreiswirth; Natalia Kurepina; James Galagan; Sebastien Gagneux; Bruce Birren; Eric J Rubin; Eric S Lander; Pardis C Sabeti; Megan Murray
Journal:  Nat Genet       Date:  2013-09-01       Impact factor: 38.330

View more
  14 in total

1.  Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.

Authors:  John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

Review 2.  Deciphering Within-Host Microevolution of Mycobacterium tuberculosis through Whole-Genome Sequencing: the Phenotypic Impact and Way Forward.

Authors:  A Van Rie; R M Warren; S D Ley; M de Vos
Journal:  Microbiol Mol Biol Rev       Date:  2019-03-27       Impact factor: 11.056

3.  Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance.

Authors:  Sanghyuk S Shin; Chawangwa Modongo; Yeonsoo Baik; Christopher Allender; Darrin Lemmer; Rebecca E Colman; David M Engelthaler; Robin M Warren; Nicola M Zetola
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

4.  Mycobacterial genomic DNA from used Xpert MTB/RIF cartridges can be utilised for accurate second-line genotypic drug susceptibility testing and spoligotyping.

Authors:  Rouxjeane Venter; Brigitta Derendinger; Margaretha de Vos; Samantha Pillay; Tanya Dolby; John Simpson; Natasha Kitchin; Ashley Ruiters; Paul D van Helden; Robin M Warren; Grant Theron
Journal:  Sci Rep       Date:  2017-11-01       Impact factor: 4.379

Review 5.  Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment.

Authors:  Anastasia Koch; Helen Cox; Valerie Mizrahi
Journal:  Curr Opin Pharmacol       Date:  2018-06-06       Impact factor: 5.547

6.  Direct transmission of within-host Mycobacterium tuberculosis diversity to secondary cases can lead to variable between-host heterogeneity without de novo mutation: A genomic investigation.

Authors:  Marie Nancy Séraphin; Anders Norman; Erik Michael Rasmussen; Alexandra M Gerace; Calin B Chiribau; Marie-Claire Rowlinson; Troels Lillebaek; Michael Lauzardo
Journal:  EBioMedicine       Date:  2019-08-13       Impact factor: 8.143

7.  How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?

Authors:  Kamela C S Ng; Philip Supply; Frank G J Cobelens; Cyril Gaudin; Julian Gonzalez-Martin; Bouke C de Jong; Leen Rigouts
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

8.  Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment.

Authors:  Camus Nimmo; Kayleen Brien; James Millard; Alison D Grant; Nesri Padayatchi; Alexander S Pym; Max O'Donnell; Richard Goldstein; Judith Breuer; François Balloux
Journal:  EBioMedicine       Date:  2020-04-28       Impact factor: 8.143

9.  Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis.

Authors:  Annelies Van Rie; John Z Metcalfe; Michael G Whitfield; David M Engelthaler; Christopher Allender; Megan Folkerts; Tim H Heupink; Jason Limberis; Robin M Warren
Journal:  J Clin Microbiol       Date:  2021-11-10       Impact factor: 5.948

10.  Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture.

Authors:  Camus Nimmo; Liam P Shaw; Ronan Doyle; Rachel Williams; Kayleen Brien; Carrie Burgess; Judith Breuer; Francois Balloux; Alexander S Pym
Journal:  BMC Genomics       Date:  2019-05-20       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.